Year-end Sale % OFF 
Abstract
Hepatocellular carcinoma (HCC) is a rare primary malignant tumor of the liver in childhood accounting for 20% to 33% of cases. Important prognostic factors are the presence of distant metastases and tumor unresectability. Currently there are no proven curative treatment options for pediatric patients with the abovementioned unfavorable prognostic factors. Authors represent a clinical case report of the HCC development with intra-abdominal metastases in an 8 years old pediatric patient. The Lenvatinib therapy with previous cytostatic therapy combined with sorafenib allowed the 6 months control over the tumor process whilst maintaining reasonably good quality of life of a patient.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
